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IS HAMPERED BY: 
-Drug resistance due to several 
mechanisms (physio-pathological, cellular 
and/or molecular) 
- Non-specific distribution, 
- Metabolization and clearance from the 
body.  
ALLOW: 
- Protection from degradation 
- Efficient targeting towards diseased 
cells  
- Better intracellular diffusion 
- Overcoming drug resistances 
- Combining various drugs or imaging 












Alkyl chain length 
 
Biodegradation 
Couvreur et al., J. Pharm. Pharmacol., 31, 331-332 (1979) Anionic polymerisation 
Opsonins 
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In vitro cytotoxicity 
(Human Hepatocellular 
Carcinoma) 
hepatocarcinoma in transgenic mice 
de Verdière, et al., Brit. J. Cancer, 76, 198-205 (1997) 
Barraud, et al.,  J. of Hepatology, 42, 736-743   (2005) 
Reddy and Couvreur, J of Hepatology, 55, 1461-1466 (2011) 
 
doxorubicine 
Patient #8: Presented with Single Unresectable Tumor in Segment II 
Tumor measured 60 x 50 mm (3000mm2)  
 
         After one infusion of 30 mg/m2, tumor necrosis was evident 
 
Survival rate is 89% after 18 months treatment 
with doxorubicin-loaded PACA nanospheres 
(LivatagR) whereas it is only  54% in patients with 
standard treatment (chimioembolization). 
Phase III: a multicentric clinical assay (40 
hospitals) 
-The independent expert committee 
recommended the continuation of the clinical trial 
for the 8th time since November 2012 
-LivatagR just obtained the « Fast Track » status 
from the FDA 
IRM Baseline 
IRM: 4 weeks post treatment 
showing tumor necrosis 
Le Droumaguet et al., ACS Nano, 6, 5866-5879 (2012a)  
Brambilla D. et al, Chem. Comm., 46, 2602-2604 (2010) 
Nicolas, J. et al., Soft Matter, 7, 6187-6193 (2011) 
Le Droumaguet et al., ACS Nano, , 6, 5866-5879 (2012) 
Alcyne 
Azide 
!« Click »! 
Le Droumaguet et al., ACS Nano, , 6, 5866-5879 (2012a) 
Target cancer cell 
Biotin  
Receptor 
MCF-7 Breast cancer 
N0 Non functionalized NP 
N1 Biotin functionalized NPs  
N1 
Huvec Healthy cells  
Le Droumaguet et al., ACS Nano, , 6, 5866-5879 (2012) 
Aβ1-42 monomer  Aβ1-42 fibrils  
N4 
Abeta 
NAD European consortium 
Collaboration M. Gobbi, Mario Negri  
and Massimo Masserini, Univ Milan 
D. Carradori, F Re, G Forloni, M Masserini, J Nicolas,  K. Andrieux, P.Couvreur, unpublished results (2016)  
NAD European consortium 
DRUG LOADING (%) 
mg drug/mg transporter material 
BURST RELEASE 
Drug molecule 
Only few nanomedicines are on the market or in phase III 
clinical trials 
P. Couvreur et al., European 
Patent, 2011 
P. Couvreur et al., US Patent, 
2011 
Extended conformation in organic solvent
Compact conformation  in water
From the « Physical » to the 
« Chemical » encapsulation paradigm 
Drug Transporter 
Linker 
THE « SQUALENOYLATION » CONCEPT 






















































































































































































































































Gem-SQ : 40% 
Dox-SQ : 58% 
 










































PenG-SQ pH : 43.8% 
PenG-SQ : 43.7% 
Anticancer drugs 
Nano Letters 2006, J Pharm Exp Ther 2008,  
Angewandte Chemie 2013, PNAS 2014, ACS Nano 2014 
Anticancer siRNA 
J Med Chem 2011, Thyroid 2014, Plos One 2014  
Antivirals 
Advanced Funct Mater 2008, Biomaterials 2013 
Antibiotics 
ACS Nano 2012, Sci Reports (Nature) 2015 















Nature Nanotechnology 2014 
J Control Release 2015 
Ad-SQ: 37% 
Maksimenko et al, PNAS, 111 (2) E217-E226 (2014) 
Nanoprecipitation are extended by the blood flow along streamlines « Loop and train » 
Human pancreatic MiaPaca 
MiaPaca 





Maksimenko et al, Proceed. Natl. Acad. Sci. USA, 111 (2) E217-E22(2014)  
Rat  hypertensive model 
Troponin 
Maksimenko et al, Proceed. Natl. Acad. Sci. USA, 111 (2) E217-E226 (2014) 
Maksimenko et al., ACS Nano, 8, 2018-2032 (2014) 
Antiangiogenic 
Cytostatic 
Maksimenko et al., ACS Nano, 8, 2018-2032 (2014) 
LS174-7 colon cancer 
๏ important role in energetic metabolism (ATP) and in 
signal transduction (AMPc) 
๏ neurotransmitter and neuromodulator 
๏ pharmacological efficacy in several neurological 
disorders 
✗     rapidly metabolized after intravenous injection 
✗     does not cross the BBB 
100 nm 
cryo-TEM sponge-like structure 
- Lepeltier et al., Langmuir, 29, 14795−14803 (2013) 
- Gaudin et al., Nature Nanotechnology, 9, 1054 (2014)  
Gaudin et al., Nature Nanotechnology, 9, 1054-1063 (2014)  
Hindlimbs paralysis 

Gaudin et al., Nature Nanotechnology, 9, 1054-1063 (2014)  
Hindlimbs paralysis 
trapped erythrocytes  
clogged capillaries 
Swollen astrocytes end-feet 
Capillary structure not preserved 
UNTREATED  AdSQ NPs 
Gaudin et al., Nature Nanotechnology, 9, 1054-1063 (2014)  Collaboration T. Dalkara (Hacettepe Univ) 
3H-Adenosine-squalene NPs  
➝ follow adenosine or its metabolites 
Adenosine-14C-squalene NPs  
➝ follow the squalene 
RT = 26,9 min 
RT = 7,3 min 
3H-Adenosine 
3H-SQAd 













Retention time (min) 
30 












Gaudin et al., Nature Nanotechnology, 9, 1054-1063 (2014) 
Gaudin et al., Chemistry of Materials, 27, 3636−3647 (2015) 
Gaudin et al., J Control Release, 212, 50-58 (2015)  
3H-Radio-HPLC 
WHICH MECHANISM OF ACTION? 
Nanoassemblies of Adenosine-Squalene extend 
Adenosine blood circulation and its interaction with 
the Neurovascular unit. This allows improving 
microcirculation reflow after occlusion with a 
cytoprotective effect on astrocytes and pericytes. 
Thus, the observed pharmacological activity in 
stroke and spinal cord injury results from rather a 
































Gaudin et al., Nature Nanotechnology, 9, 1054-1063 (2014)  
Ad free injection: absence of Ad, 
even 1 min after iv injection 
FRET 
< 100 Å 
NO FRET 
baso-lateral compartment (DOWN) 
apical compartment (UP) 
> 100 Å 
⤹ 
✓ NPs are disassembled inside the cells and exocytosed in 
the brain parenchyma in a molecular form 
Are NPs intact during cell internalization? 
donor acceptor 
donor excitation acceptor emission FRET 
hCMEC/D3 
cells (barrier) 
Are NPs intact after crossing the BBB? 
Collaboration Dr Oya Tagit and Pr Niko Hilldebrandt –  
NanoBioPhotonics, Orsay, France 
Gaudin et al., Nature Nanotechnology, 9, 1054-1063 (2014) 
Gaudin et al., Chemistry of Materials, 27, 3636−3647 (2015) 
« On demand » spatio-temporal drug 
release control 
Endogenous stimuli Exogenous stimuli 
• pH 
• Redox status (glutathion 
concentrations) 
• Enzymatic activity 
• Magnetic field 
• Electric field 
• Light  
• Ultrasound 
• Temperature 
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gemcitabine (       ) 
Untreated (          ) 
SQgem nanoassemblies (         ) 
Mag-SQgem composite nanoassemblies (        ) 
Mag-SQgem composite nanoassemblies (without magnet) (       ) 
 Arias et al., ACS Nano, 22, 1513-1521 (2011)  
magnet tumor 
« NANOTHERAGNOSTICS» ! 
5 mg/Kg 
Ultrasmall iron oxide nanoparticles 























Pénicilline G Squal hydrolysable








Untreated PENG free treated PENG-SQ NPs treated 
Semiramoth et al.,  ACS Nano, 6, 3820-3831 (2012) 
Nabed et al., Scientific Reports (Nature), doi:10.1038/srep13500 
(2015)  























































Iron  Collaboration G Ferey and C. Serre 
Horcajada et al., Nature Materials, 9, 172-178 (2010) 
Mc Kinley et al., Angew. Chem. Int. Ed. , 23, 6260-6266 (2010) 
Horcajada et al., Chem Rev. , 112, 1232-1268 (2012) 
 
MIL-100 MIL-88A 
1.  Target diseased area  
2. Overcome resistance to 
treatments 
3.  Combine various functionalities 
(ie. multitherapy or therapy + 
imaging etc.) 
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